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Abstract: Background: Previous studies have demonstrated elevated levels of excitatory amino acids (EAA) glutamate (Glu) and aspartate (Asp) in the synovial fluid (SF) of patients with active arthritis. The source of SF EAA
concentrations are thought in large part to be secondary to passive diffusion from the plasma across synovial membranes and less so, reflective of local synovial pathology. Objective: This descriptive report assesses the hypothesis
that the SF EAA levels reflect inflammatory processes of the joint and are not dependent on plasma levels. Methods:
Simultaneously drawn plasma and SF samples were obtained from 14 recently deceased cadavers and 10 patients
with active arthritis. Plasma and SF EAA and other amino acid (AA) levels were determined by HPLC. SF: Plasma
compartment concentration ratios were calculated to assess if SF EAA levels were similar to plasma levels. Results:
In the cadavers with no antemortem arthritis, the mean SF: Plasma ratios for Glu and Asp were 4-5-fold lower than
the mean ratios seen for 9 other AAs, showing specific discrepancies of EAA levels between plasma and synovial
fluid. In 9 patients with active arthritis, the SF: Plasma concentration ratios were higher in samples derived from
inflammatory arthropathies. Conclusions: Clinical samples demonstrated distinct, independent compartmental EAA
concentrations between blood and joint compartments in support that local arthritic processes rather than plasma
influence SF EAA concentrations. The SF EAA levels, whether from local cell production, local neurogenic sources,
and/or transport-gradient mechanisms, parallel local pathology in the joint compartment and thus serve as surrogate biomarkers of local inflammatory processes.
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Introduction
Previous studies have demonstrated elevated
levels of excitatory amino acids (EAA) and other
neurotransmitters in synovial fluid (SF) extracted from patients with active arthritic conditions
[1-3] [McNearney TA, Goel N, Lisse JL, Speegle
D, Cao S and Westlund KN. Neurotransmitter
excitatory amino acids in synovial fluids demonstrate distinct temporal fluctuations in active
arthritis, submitted]. Additional studies have
reported elevated plasma amino acid (AA) levels in patients with rheumatoid arthritis compared to normal controls [4]. The source(s) of
increased SF EAA levels is not known but possibilities include local cell production, neurogenic exudation, or passive diffusion from the

blood or plasma across synovial membranes.
The concentration elevations of SF EAA in
symptomatic arthropathies and their reported
association with SF RANTES, and MIP1-alpha
concentrations promotes the hypothesis that
local inflammatory joint processes rather than
passive diffusion from plasma determines SF
EAA concentrations [5]. To assess this, simultaneously drawn plasma and synovial fluids from
the knees of 14 recently deceased cadavers
and 9 patients with active arthritis were
obtained and measured for EAA and other AA
levels to assess the compartmental SF: Plasma
concentration ratios. Disparate ratios between
these compartments would support the concept that EAA and other AA levels are primarily
determined by local inflammatory arthritic pro-

EAA compartmental differences reflect arthritis

Figure 1. A: SF: Plasma ratios of 12 amino acid concentrations (µM) determined by HPLC derived from 14 cadavers. SF: Plasma ratios are shown as mean values +/- standard error. EAA: glutamate (Glu); aspartate (Asp) and
glutamine (Gln). Other amino acids include serine (Ser); glycine (Gly); arginine (Arg); citrulline (Ctn); threonine (Thr);
alanine (Ala); tyrosine (Tyr); taurine (Tau) and asparagine (Asn). *: p<0.01 comparing the mean Glu SF: Plasma ratio
to non EAA amino acids. **: p<0.01 comparing the mean Asp SF: Plasma ratio to non EAA amino acids. These data
support compartmental differences for EAA relative to other AA. B: SF: Plasma ratios of amino acid concentrations
(µM) of plasma and knee SF determined by HPLC derived from a patient with active Reiter’s syndrome. SF: Plasma
ratios are shown as mean values +/- standard error. In a patient with active inflammatory synovitis, the mean SF:
Plasma ratios for EAA were much higher compared to the ratios of other amino acids. *: p<0.01 comparing the
mean Glu SF: Plasma ratio to non EAA amino acids. **: p<0.01 comparing the mean Asp SF: Plasma ratio to non
EAA amino acids.

cesses and are independent of the plasma
concentrations.
Materials and methods
Informed consent
All clinical samples collected and medical
record reviews were under approved protocols
by the University of Texas Medical Branch
Institutional Review Board (IRB) with appropriately authorized informed consent.
Cadavers
Autopsy specimens were considered acceptable for study if samples were harvested within
24 hours after witnessed death. Written consent was obtained from the family or authorized
persons for fluid harvest, medical record review,
and physical examination before plasma and
synovial fluids were harvested, per IRB protocol. Cadaveric samples (N=14) were available
for which there was no clinical or antemortem
history of active arthritis at the time of death.
Blood was obtained by venipuncture or cardiac
puncture, as routinely obtained for autopsy
cases in tubes with EDTA. Synovial fluids were
obtained by introduction of a 16-gauge needle
below the patella and aspiration of the joint
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fluid. In nonedematous or nonarthritic conditions, the synovial fluid harvest was usually
between 0.5-2.0 ml of viscous, clear, or pale
yellow fluid. In patients with peripheral (generalized) edema or antemortem arthritic conditions, it was possible to harvest larger volumes
(5-8 ml) of fluid from the knee joints.
Patients
After written consent was obtained, SF from
the active arthritic knee was obtained at the
time of diagnostic or therapeutic arthrocentesis. Venipuncture was performed simultaneously. Sample processing has been previously
described [3]. The arthritic conditions were
diagnosed by faculty members of the University
Rheumatology division based on diagnostic criteria [6]. These included: rheumatoid arthritis,
acute gout, acute Reiters syndrome, osteoarthritis, pseudogout and sympathetic effusion in
a patient with catastrophic antiphospholipid
antibody syndrome (APAS).
High pressure liquid chromatography (HPLC),
experimental standards and quality control
The protocols, standards and internal controls
for HPLC determination have been previously
described [3].
Int J Clin Exp Pathol 2013;6(3):492-497
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Quantities (in μM) from HPLC are presented as
the mean SF: Plasma EAA concentration ratios
or mean SF: Plasma AA concentration ratios.
The neurotransmitter EAA’s measured were
glutamate (Glu) and aspartate (Asp). Other AAs
measured included serine (Ser) and glycine
(Gly), as neurotransmitter inhibitory amino
acids (IAA) and AA used as metabolic controls:
glutamine (Gln), arginine (Arg), threonine (Thr),
alanine (Ala), taurine (Tau), tyrosine (Tyr) and
asparagine (Asn).
Statistics
Each sample had three determinations. Data
are presented as average values +/- SE.
Analyses of concentrations were determined by
Mann-Whitney U tests. A p value <0.05 was
considered significant. Average SF: Plasma
concentration ratios were also determined and
plotted with positive values showing higher values in the joint and negative values showing
higher values in the plasma (blood).
Results
Mean SF: plasma EAA concentration ratios
demonstrate significant compartmental disparity
Figure 1A depicts the mean SF: Plasma concentration ratios of the EAA and other AA from
14 cadavers without evidence of active antemortem arthritis. The mean SF: Plasma concentration ratios for 14 cadaveric samples
were <1 for all EAA and other AA, However, the
mean SF: Plasma concentration ratio disparity
for Glu was much greater compared to the
other AA (Glu: -22.15-fold, p<0.01 compared to
all other AA except Asp). The mean Asp SF:
Plasma concentration ratios were much greater for other AA except for Tau, (Asp: -17.16-fold
p<0.01 all non EAA except Tau; Asp vs. Tau p=
0.059). The mean SF: Plasma concentration
ratios of other AA’s were much less disparate
and are as follows: Gln: -1.61; Ser: -3.96; Gly:
-2.11; Arg: -0.68; Ctn: -2.13; Thr: -1.92; Ala:
-2.69; Tau: -1.57; Tyr: -5.71 and Asn: -1.93.
Nonarthritic cadaver SF Glu and Asp levels
were in close agreement with previously reported baseline levels [3]. For all cadavers with no
antemortem arthritis, mean SF Glu concentrations ranged from 0.28 - 26.26 µM and mean
Asp concentrations ranged from 0 - 11.93 μM.
From the plasma samples, mean plasma Glu
494

concentrations ranged from 9.48 - 80.50 µM
and mean plasma Asp concentration ranged
from 0 - 73.36 µM among the cadavers.
Figure 1B depicts the mean EAA and other AA
SF: Plasma concentration ratios from samples
derived from a patient with acute Reiter’s syndrome. The mean SF: Plasma concentration
ratio for Glu: 7.50±0.18-fold, p<0.01 compared
to all AA except Asp. The mean Asp SF: Plasma
concentration ratios for Asp: 4.49±0.39-fold
p<0.01, compared to other AA except Glu. The
samples from the patient with acute Reiter’s
syndrome with symptomatic synovitis demonstrates that higher SF EAA concentrations
reflect the intense inflammatory pathology of
the joint compartment relative to the plasma
concentrations (blood compartment) in this
systemic illness.
Figure 2 demonstrates mean SF: Plasma EAA
concentration ratios of 9 patients with active
arthritis or synovial effusion who underwent
simultaneous blood draws and arthrocenteses.
Patient 1 had Reiter’s syndrome (RS); patients
2 and 3 had rheumatoid arthritis (RA); patients
4 and 5 had acute gout; patients 6 and 7 had
osteoarthritis; patient 8 had pseudogout (PG)
and patient 9 had a sympathetic synovial effusion from complications of antiphospholipid
antibody syndrome (APAS). Patients 1-5 generally had mean SF: Plasma EAA concentration
ratios >1, reflecting higher SF EAA concentrations in the joint compartment. Patients 6-9
had arthritic conditions with mean SF: Plasma
ratios <1, reflecting lower inflammatory arthritic
activity. relative to any systemic processes.
Patients 8 and 9 had severe systemic illnesses
(acute bacterial pneumonia and catastrophic
APAS, respectively) which resulted in significantly higher concentrations of plasma EAA
and other AA. Thus, these patients had lower
mean SF: Plasma ratios (<1), as inordinately
higher plasma EAA levels reflected severe systemic illnesses. To serve as templates, the far
right of the graph depicts SF: Plasma concentration ratios from cadaveric samples from a RA
patient who had active synovitis at the time
death (+) and from a patient who had no antemortem history of active arthritis (-). Table 1 is
a summary of the pertinent clinical laboratory
results of the nine patients from whom the
samples were derived, including the SF WBC
counts, which serve as inflammatory indices for
synovial effusions. Table 1 also demonstrates
Int J Clin Exp Pathol 2013;6(3):492-497
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Table 1. Summary of patient diagnoses, age and cell counts
Patient #
Diagnosis
Age, yrs
Pl WBC #
SF WBC #
SF Lym #
Intracell. Crystals

1
RS
37
10
44.0
3.15
---

2
RA
73
8.0
6.0
0.24
---

3
RA
29
6.9
31.0
1.5
---

4
Gout
63
13.6
19.2
NA
++ UA

5
Gout
67
6.5
31.0
0.3
++ UA

6
OA
54
NA
NA
NA
---

7
OA
41
8.6
280
002
---

8
PG
79
8.1
0.33
0.04
++ CPPD

9
APAS
27
6.3
0.123
0.006
---

Diagnosis: RS: Reiters syndrome, RA: rheumatoid arthritis, SLE: systemic lupus erythematosus; OA: osteoarthritis, PG: pseudogout, APAS: antiphospholipid antibody syndrome; Age: in years; Pl WBC #: plasma white blood cell count, /mm3x1000; SF WBC
#: synovial fluid white blood cell count /mm3x1000; SF Lym. #: synovial fluid lymphocyte count/mm3x1000. Intracell. Crystals:
intracellular crystals in SF, UA: uric acid crystals, CPPD: intracellular calcium pyrophosphate dihydrate; ND: not done.

tions in patients with active arthritis. The
sources of elevated SF Glu and Asp concentrations in active arthritis are unknown,
but likely candidates include plasma, local
production from synoviocytes or osteocytes in the joint capsule or local secretion from nerve fibers. One might expect
that SF Glu and Asp would be in full equilibrium with the plasma, based on size, as
small physiologic molecules are usually in
full equilibrium between plasma and synovial fluid [7]. However, the samples from
the cadavers with no antemortem arthritis
had significantly decreased EAA SF:
Plasma concentration ratios compared to
nine other AA. The significantly greater
compartmental ratio differences of SF Glu
and Asp indicate that plasma is not the
Figure 2. SF: Plasma ratios of amino acid concentrations (µM)
sole or even major source of SF EAA.
of plasma and knee SF determined by HPLC derived from patients with active arthritis. SF: Plasma ratios are shown as
Higher SF: Plasma concentration ratios in
mean values +/- standard error. The lanes depict patients with,
one cadaver with antemortem arthritis
1: Reiter’s syndrome (RS); 2 and 3: rheumatoid arthritis (RA); 4
and several patients with active inflammaand 5: acute gout; 6 and 7: osteoarthritis (OA); 8: pseudogout
tory arthritic processes also support the
(PG) and 9: sympathetic effusion in a patient with antiphoshypothesis that SF EAA concentrations
pholipid antibody syndrome (APAS). The values above the xaxis are conditions where the EAA concentrations are higher in
reflect local physiologic processes in the
the joint fluid compared to blood. The values below the x-axis
joint. High AA concentrations obtained in
represent conditions where the plasma EAA values are higher
several cadaver plasma samples might be
than the SF levels. Closed bars depict glutamate (Glu); open
explained by antemortem systemic inflambars depict aspartate (Asp).
matory conditions or possibly reflect postmortem hemolysis and cytolysis. However,
that blood WBC counts or SF white cell counts
the mean plasma concentrations of cadavers
alone do not account for the SF or plasma EAA
with no active antemortem infectious or inflamconcentrations or the SF: Plasma EAA concenmatory conditions are in close agreement to
tration ratios.
the plasma levels obtained from 15 normal
healthy controls (Data not shown). Moreover,
Discussion
SF samples with no antemortem arthritis are in
close agreement to baseline levels obtained in
This descriptive study is the first to assess the
healthy rats (Data not shown).
relative compartmental concentrations of
The SF: Plasma EAA ratio discrepancies might
amino acids between plasma and synovial fluid
also reflect the necessity of energy dependent
and indicates a clinical compartmental releglutamate transporter proteins in peripheral
vance to increased SF Glu and Asp concentra495
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tissues, including bone, cartilage and synovium
[8-10]. Sodium or potassium dependent Glu
and Asp transport proteins may play role in the
maintenance of SF EAA concentrations in the
normal joint. In the CNS, high affinity glutamate/aspartate carrier proteins are capable of
transporting the neurotransmitters against several thousand fold concentration gradients
using the sodium, potassium electrochemical
gradient as a driving force, under control conditions [11]. Persistent depolarization of nerves
reverses the function of the Glu transporter
pumps, however, resulting in a dumping of
amino acids [12, 13]. Microdialysis uptake of
inflammatory perturbations may also induce
local synovium-based carrier proteins to inappropriately allow an increased influx of normally
excluded substances from the plasma, including Glu and Asp. Alternatively, the Glu and Asp
may require additional mechanisms to migrate
through the SF, and its accumulation points to
a failure of normal exclusion physiology during
joint inflammation. In addition to EAA sources
from the plasma, SF Glu and Asp concentrations are secondary to local production by resident cells in the joint capsule [14, 15].
A more likely source may be the stimulated
release from the primary afferent nerve terminals supplying the joint, as is thought for substance P release into the joint [16]. Substance
P has been demonstrated to have SF: Plasma
ratios of 2-fold in an inflammatory arthropathy
[17]. The SF EAA values derived from normal rat
suggest that the low values might be physiologic in the absence of active arthritis and are
elevated in inflamed joints [18, 19]. Previous
studies have demonstrated increased Glu
immunoreactivity in the median articular nerve
supplying inflamed joints of monkeys [20].
Thus, it is reasonable to assume that glutamate might also be released into the joint by
nerve fibers. In a k/c induced arthritis model in
rats, the expected increase in SF Glu was abrogated with pretreatment with intra-articular
lidocaine, which decreases neurotransmitter
release from peripheral nerves [18]. Local glutamate and aspartate can bind and activate
peripheral receptors on local osteocytes, chondrocytes and synoviocytes to enhance or perpetuate local inflammation and pathologies
[15, 19, 21-25]. In a previous study, our group
demonstrated a correlation between SF EAA
levels and SF RANTES, MIP1-alpha and IL-8 lev496

els [5]. In the same study, SF WBC counts significantly correlated to SF IL-8 levels but not to
EAA levels.
The disparity of EAA levels between body compartments in this study demonstrates a spectrum of host pathologic processes and supports a physiologic relevance of the EAA levels
and their regulation in the joint. Taken together,
SF EAA elevations reflect the dynamics of joint
inflammation and pain. Further studies might
identify SF EAA concentrations as novel direct
or surrogate biomarkers that reflect local pathologic arthritic processes.
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